Drug Profile

AVT 001

Alternative Names: AVT-001

Latest Information Update: 26 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avotres
Class Antihyperglycaemics; Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Type 1 diabetes mellitus

Most Recent Events

19 Dec 2023 Avotres completes a phase I/II trial in Type 1 diabetes mellitus (In adolescents, In adults, In the elderly) in USA (IV) (NCT03895996)
02 Oct 2023 Safety and efficacy data from a phase I/II trial in Type 1 diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
19 Jul 2023 Efficacy and adverse events data from a phase-I/II trial in Type 1 diabetes mellitus released by Avotres

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com